Quinolones in pediatrics: Viewpoint of a clinical pharmacologist

P. S. Lietman

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


It is clearly time, in October of 1995, and 8 years after the first of the fluoroquinolone antibiotics was approved by the FDA and marketed in the U.S., to consider the status of fluoroquinolones for children. In these 8 or more years, have we protected children from the ravages of these dangerous drugs? Or, at the other extreme, have children died of, or suffered greatly from, bacterial diseases against which a fluoroquinolone would likely have been effective? And exactly where are we now with respect to the development of fluoroquinolones for children? Are any about to be marketed for children? Or are we about to begin the lengthy process of drug development? Or are we ready to conclude that they simply aren't needed for children and therefore need not be studied in children or marketed for children?.

Original languageEnglish (US)
Pages (from-to)24-27
Number of pages4
JournalChemotherapie Journal, Supplement
Issue number13
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)


Dive into the research topics of 'Quinolones in pediatrics: Viewpoint of a clinical pharmacologist'. Together they form a unique fingerprint.

Cite this